Medication nonadherence is a pricing problem, not a willpower problem

Ask a physician why a patient didn't fill a prescription, and the answer usually lands on the patient: forgot, or never took the diagnosis seriously enough. Ask the pharmacist who watched it happen, and the answer is a number. The patient reached the counter, heard what the medication cost and left without it. Both are accounts of the same missed fill. The pharmacist is describing a price and was close enough to watch it decide the outcome.

The data puts the price first. A peer-reviewed Health Affairs study of HIV pre-exposure prophylaxis (PrEP) prescriptions found that abandonment ran at 5.5% when a new prescription carried no out-of-pocket cost and reached 42.6% once the cost passed $500. Moving from zero to just $10 was enough to roughly double it. The steepest part is the first dollar, where even a token charge behaves like a cliff. And the patient usually meets that first dollar after leaving the exam room, with no context for it and no route to a lower number.

Here is why the pricing problem persists. The industry measures cost the way it measures everything about adherence: in retrospect, through refill rates and gaps in therapy read weeks or months later. By then, the price has already turned the patient away, and the refill the system is waiting for was never going to come. We have grown precise at documenting the failure and slow to reach the moment that caused it. The number that decides the fill is knowable while the prescription is being written. We keep checking for it at the pharmacy, after it has already done its work.

Prior authorization sits in the same blind spot. In the American Medical Association's 2024 prior authorization survey, 78% of physicians reported that prior authorization often or sometimes leads patients to abandon a recommended course of treatment. The treatment was right, and the patient wanted it. The delay between the prescription pad and the pharmacy counter wore them down first, in the same window the refill data never sees.

Measuring the moment that matters means acting in it. The cost of a prescription, and whether coverage will clear, belong in the exam room while the physician and patient are still together and able to choose differently. A patient who learns the price with the prescription, alongside the affordable path to it, is making a different decision than a patient who meets that price alone at a counter days later. The coverage obstacle is worth surfacing there too, early enough to act on before it becomes a denial and a second visit. And because the choice runs through both the prescriber and the patient, reaching only one of them leaves the moment half-addressed.

The pieces to do this are within reach. What is rare is bringing them together at the decision moment and then following the outcome all the way through. Offering a patient help and confirming that the patient started therapy are both worth measuring, and the second is the one the industry usually leaves out. Patient education belongs in that mix, though education alone cannot clear a price the patient cannot pay. The spend that reaches the exam room has to carry the affordable path alongside the message.

For physicians, this reshapes the first question. When a patient does not fill a prescription, cost, coverage or authorization friction deserves to be the leading assumption, ahead of forgetfulness, because that is where the evidence keeps pointing. It is worth demanding of the tools physicians are handed, too: Surface the price and the affordable path in the room, and flag the coverage barrier early enough to act on it, before the visit ends. For the health systems, payers and manufacturers that build those tools, the real question is which outcome they are willing to be judged on. A patient who started and stayed on therapy is the one that settles it. Every measure taken before then is a proxy for that patient and worth only as much as it moves them.

Kamya Elawadhi is co-founder and president of Doceree.